Evaluation of Alendronate Efficacy on Bone Mineral Density in Thalassemic Patients

Introduction: Thalassemia is the most common genetic disorder, affecting around 200 million people worldwide. The etiology of this bone disease is multifactorial. Seemingly, in the setting of increased bone turnover which manifests by increased bone resorption and remodeling; bone density decreases....

Full description

Bibliographic Details
Main Authors: Fatemeh Shirani, Mahin lashkari, Ali Shahriari Ahmadi, Mohsen Arabi, Nastaran Asefi
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2012-10-01
Series:International Journal of Hematology-Oncology and Stem Cell Research
Subjects:
BMD
Online Access:http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/346/353
id doaj-be1c6cf1867f4ab483ac54d14794c734
record_format Article
spelling doaj-be1c6cf1867f4ab483ac54d14794c7342020-11-25T04:01:43ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-30092008-22072012-10-01642024Evaluation of Alendronate Efficacy on Bone Mineral Density in Thalassemic PatientsFatemeh ShiraniMahin lashkariAli Shahriari AhmadiMohsen ArabiNastaran AsefiIntroduction: Thalassemia is the most common genetic disorder, affecting around 200 million people worldwide. The etiology of this bone disease is multifactorial. Seemingly, in the setting of increased bone turnover which manifests by increased bone resorption and remodeling; bone density decreases. In this research, thalassaemia patients with osteoporosis were placed on oral alendronate therapy for one year and their pre-and post-study bone mineral densitometry were compared.Method: Thalassaemia patients, comprising the major and intermedia types, in the range of 20 to 50 years old were included in the study. They were admitted to three different centers: Tehran Center of Thalassaemia, Iranian Blood Transfusion Organization and the Rheumatology Clinic of Rasool Akram(s) Hospital. First of all, osteoporotic patients diagnosed on the basis of densitometry were placed on oral regimen of 10mg of alendronate daily. After a year, their densitometries were repeated and compared for the changes in BMD(g/cm2) and T-score. Also, patient’s serum calcium, phosphorus and alkaline phosphatase levels were measured at the beginning and the end of the year and the results were compared.Results: Ninety-six of 120 patients who underwent first and second bone density measurements showed an increase in BMD and T-score at the end of the study. BMD increased in patients who used their drugs regularly, while no increased BMD was found in patients who used drugs irregularly or essentially did not use any drug.Conclusion:, we concluded that bisphosphonates like alendronate are highly effective at improving bone density of neck of femur and vertebral bones without having dangerous side effects. So, early diagnosis, treatment and prophylaxis of osteoporosis in this group of patients are highly recommended.http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/346/353ThalassaemiaOsteoporosisBMDAlendronate
collection DOAJ
language English
format Article
sources DOAJ
author Fatemeh Shirani
Mahin lashkari
Ali Shahriari Ahmadi
Mohsen Arabi
Nastaran Asefi
spellingShingle Fatemeh Shirani
Mahin lashkari
Ali Shahriari Ahmadi
Mohsen Arabi
Nastaran Asefi
Evaluation of Alendronate Efficacy on Bone Mineral Density in Thalassemic Patients
International Journal of Hematology-Oncology and Stem Cell Research
Thalassaemia
Osteoporosis
BMD
Alendronate
author_facet Fatemeh Shirani
Mahin lashkari
Ali Shahriari Ahmadi
Mohsen Arabi
Nastaran Asefi
author_sort Fatemeh Shirani
title Evaluation of Alendronate Efficacy on Bone Mineral Density in Thalassemic Patients
title_short Evaluation of Alendronate Efficacy on Bone Mineral Density in Thalassemic Patients
title_full Evaluation of Alendronate Efficacy on Bone Mineral Density in Thalassemic Patients
title_fullStr Evaluation of Alendronate Efficacy on Bone Mineral Density in Thalassemic Patients
title_full_unstemmed Evaluation of Alendronate Efficacy on Bone Mineral Density in Thalassemic Patients
title_sort evaluation of alendronate efficacy on bone mineral density in thalassemic patients
publisher Tehran University of Medical Sciences
series International Journal of Hematology-Oncology and Stem Cell Research
issn 2008-3009
2008-2207
publishDate 2012-10-01
description Introduction: Thalassemia is the most common genetic disorder, affecting around 200 million people worldwide. The etiology of this bone disease is multifactorial. Seemingly, in the setting of increased bone turnover which manifests by increased bone resorption and remodeling; bone density decreases. In this research, thalassaemia patients with osteoporosis were placed on oral alendronate therapy for one year and their pre-and post-study bone mineral densitometry were compared.Method: Thalassaemia patients, comprising the major and intermedia types, in the range of 20 to 50 years old were included in the study. They were admitted to three different centers: Tehran Center of Thalassaemia, Iranian Blood Transfusion Organization and the Rheumatology Clinic of Rasool Akram(s) Hospital. First of all, osteoporotic patients diagnosed on the basis of densitometry were placed on oral regimen of 10mg of alendronate daily. After a year, their densitometries were repeated and compared for the changes in BMD(g/cm2) and T-score. Also, patient’s serum calcium, phosphorus and alkaline phosphatase levels were measured at the beginning and the end of the year and the results were compared.Results: Ninety-six of 120 patients who underwent first and second bone density measurements showed an increase in BMD and T-score at the end of the study. BMD increased in patients who used their drugs regularly, while no increased BMD was found in patients who used drugs irregularly or essentially did not use any drug.Conclusion:, we concluded that bisphosphonates like alendronate are highly effective at improving bone density of neck of femur and vertebral bones without having dangerous side effects. So, early diagnosis, treatment and prophylaxis of osteoporosis in this group of patients are highly recommended.
topic Thalassaemia
Osteoporosis
BMD
Alendronate
url http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/346/353
work_keys_str_mv AT fatemehshirani evaluationofalendronateefficacyonbonemineraldensityinthalassemicpatients
AT mahinlashkari evaluationofalendronateefficacyonbonemineraldensityinthalassemicpatients
AT alishahriariahmadi evaluationofalendronateefficacyonbonemineraldensityinthalassemicpatients
AT mohsenarabi evaluationofalendronateefficacyonbonemineraldensityinthalassemicpatients
AT nastaranasefi evaluationofalendronateefficacyonbonemineraldensityinthalassemicpatients
_version_ 1724445478638059520